Compare RVSB & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVSB | CALC |
|---|---|---|
| Founded | 1923 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.8M | 91.5M |
| IPO Year | 1993 | N/A |
| Metric | RVSB | CALC |
|---|---|---|
| Price | $5.32 | $6.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $7.00 | ★ $14.50 |
| AVG Volume (30 Days) | 45.4K | ★ 144.6K |
| Earning Date | 01-29-2026 | 11-12-2025 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | ★ 361.12 | N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $52,756,000.00 | N/A |
| Revenue This Year | $10.25 | N/A |
| Revenue Next Year | $11.23 | N/A |
| P/E Ratio | $24.09 | ★ N/A |
| Revenue Growth | ★ 15.20 | N/A |
| 52 Week Low | $4.74 | $1.42 |
| 52 Week High | $6.59 | $6.40 |
| Indicator | RVSB | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 51.06 | 76.69 |
| Support Level | $5.01 | $4.64 |
| Resistance Level | $5.62 | $5.34 |
| Average True Range (ATR) | 0.18 | 0.51 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 50.00 | 90.04 |
Riverview Bancorp Inc is an American savings and loan holding company. The company through its subsidiaries engages in the business of attracting deposits and puts it to use in its market area to originate commercial business. It is organized into two operating segments, Banking Operations performed by the bank and trust and Investment Services performed by the Trust company. The company products and services include checking, saving, money market, mortgage, home equity, consumer, online banking, cash management, and others.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.